Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $1.9833.

A number of research firms have recently weighed in on NMTC. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. JonesTrading initiated coverage on NeuroOne Medical Technologies in a research report on Monday. They issued a “buy” rating and a $1.50 price target for the company. Finally, Zacks Research upgraded NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th.

Insiders Place Their Bets

In related news, insider David J. Wambeke purchased 1,000,000 shares of the stock in a transaction that occurred on Sunday, March 1st. The stock was bought at an average cost of $0.67 per share, for a total transaction of $670,000.00. Following the completion of the transaction, the insider directly owned 1,000,000 shares in the company, valued at $670,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Large investors have recently made changes to their positions in the company. Sio Capital Management LLC purchased a new stake in NeuroOne Medical Technologies in the 2nd quarter worth about $2,390,000. Vanguard Group Inc. grew its stake in shares of NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares during the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of NeuroOne Medical Technologies in the fourth quarter worth approximately $143,000. Virtu Financial LLC bought a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter worth approximately $88,000. Finally, Goldman Sachs Group Inc. purchased a new position in NeuroOne Medical Technologies during the 1st quarter valued at $84,000. 16.07% of the stock is owned by hedge funds and other institutional investors.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $0.79 on Monday. The company has a market cap of $39.92 million, a price-to-earnings ratio of -4.65 and a beta of 0.74. NeuroOne Medical Technologies has a 1 year low of $0.40 and a 1 year high of $1.16. The stock’s 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $0.79.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.